I have long been researching plant medicine, especially cannabis as a cancer treatment. During the pandemic, after ivermectin's anti-viral effects became widely-known (despite media lies), I heard rumors of its effectiveness as a cancer treatment. I then started to research more into it, and sure enough it's true. The scientific literature shows good evidence of ivermectin as a chemotherapeutic, so much that researchers have discussed repurposing it as such, especially in combination with other pharmaceuticals.

How does Ivermectin treat gynecological cancer?

PAK1 is an oncogenic kinase required for the growth of 3/4 of human cancer, including colon, breast, pancreatic, and ovarian cancer. Ivermectin blocks PAK1 in human ovarian cancer cells to suppress tumor growth (Hashimoto, 2009). Another study by Li and Zhan (2020) found ivermectin supresses ovarian cancer by regulating lncRNA-EIF4A3-mRNA axes. Ivermectin alone has shown to alter energy metabolism pathways of epithelial ovarian carcinoma to inhibit the cell's cycle progression and proliferation and to induce apoptosis (Li et al, 2020).

"The combination of Paclitaxel with Pitavastatin or Ivermectin showed the highest cytotoxic effect and the strongest synergism among all combinations for both chemoresistant cell lines, resulting in a chemotherapeutic effect superior to both drugs alone. Almost all the repurposed drugs in combination with Paclitaxel presented a safe pharmacological profile in non-tumoral cells. Overall, we suggest that Pitavastatin and Ivermectin could act synergistically in combination with Paclitaxel, being promising two-drug combinations for high-grade serous carcinoma management." -Nunes et al, 2022

There is quite a bit of research of ivermectin treating ovarian cancer in combination with other drugs such as bisphosphonate (osteoperosis drug), metformin (anti-diabetic), itraconazole (anti-fingal), NSAIDS (Kobayashi, 2019). A 2022 study found that Ivermectin enhanced the anticancer effects of Paclitaxel in chemo-resistant high-grade serous carcinoma (Nunes et al). It can can also significantly inhibit the viability of HeLa cervical cancer cell lines through DNA fragmentation and cell cycle arrest, according to Zhang et al (2019). I have yet find any studies about uterine cancer, but I will be sure to do an update if any data comes out.

Sources:

Hashimoto, H., Messerli, S. M., Sudo, T., & Maruta, H. (2009). Ivermectin inactivates the kinase PAK1 and blocks the PAK1-dependent growth of human ovarian cancer and NF2 tumor cell lines. Drug discoveries & therapeutics, Vol 3(6), pp. 243–246.

Kobayashi Y, Banno K, Kunitomi H, Tominaga E, Aoki D (2019). Current state and outlook for drug repositioning anticipated in the field of ovarian cancer. Journal of Gynecological Oncology. Vol 30(1):e10. doi: 10.3802/jgo.2019.30.e10.

Li N, Li H, Wang Y, Cao L, Zhan X (2020). Quantitative proteomics revealed energy metabolism pathway alterations in human epithelial ovarian carcinoma and their regulation by the antiparasite drug ivermectin: data interpretation in the context of 3P medicine. EPMA Journal. Vol 11(4), pg. 661-694. doi: 10.1007/s13167-020-00224-z.

Li N, Zhan X (2020). Anti-parasite drug ivermectin can suppress ovarian cancer by regulating lncRNA-EIF4A3-mRNA axes. EPMA Journal. Vol.11(2), pg. 289-309. doi: 10.1007/s13167-020-00209-y.

Nunes M, Henriques Abreu M, Bartosch C, Ricardo S (2020). Recycling the Purpose of Old Drugs to Treat Ovarian Cancer. International Journal of Molecular Science. Vol 21(20), pg. 7768. doi: 10.3390/ijms21207768.

Nunes M, Duarte D, Vale N, Ricardo S (2022). Pitavastatin and Ivermectin Enhance the Efficacy of Paclitaxel in Chemoresistant High-Grade Serous Carcinoma. Cancers (Basel). Vol 14(18), pp. 4357. doi: 10.3390/cancers14184357.

Zhang P, Zhang Y, Liu K, Liu B, Xu W, Gao J, Ding L, Tao L (2019). Ivermectin induces cell cycle arrest and apoptosis of HeLa cells via mitochondrial pathway. Cell Proliferation. Vol 52(2):e12543. doi: 10.1111/cpr.12543.

---

_{Posted from https://blurtlatam.intinte.org}